Management of adult patients with ascites due to cirrhosis: an update.

GUIDELINE TITLE
Management of adult patients with ascites due to cirrhosis: an update.

BIBLIOGRAPHIC SOURCE(S)
Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009 Jun;49(6):2087-107. [174 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004 Mar;39(3):841-56. [110 references]

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

April 14, 2009 - Rocephin (ceftriaxone sodium): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Based on the results from recent in vitro studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

abrir aquí para acceder al documento NGC AHRQ completo:
Management of adult patients with ascites due to cirrhosis: an update.